Determinants of morbidity and mortality related to health care-associated primary bloodstream infections in neonatal intensive care units: a prospective cohort study from the SEPREVEN trial.

bloodstream infections coagulase-negative staphylococci newborn outcomes preterm

Journal

Frontiers in pediatrics
ISSN: 2296-2360
Titre abrégé: Front Pediatr
Pays: Switzerland
ID NLM: 101615492

Informations de publication

Date de publication:
2023
Historique:
received: 21 02 2023
accepted: 10 05 2023
medline: 16 6 2023
pubmed: 16 6 2023
entrez: 16 6 2023
Statut: epublish

Résumé

Health care-associated primary bloodstream infections (BSIs), defined as not secondary to an infection at another body site, including central line-associated BSI, are a leading cause of morbidity and mortality in patients in neonatal intensive care units (NICUs). Our objective was to identify factors associated with severe morbidity and mortality after these infections in neonates in NICUs. This ancillary study of the SEPREVEN trial included neonates hospitalized ≥2 days in one of 12 French NICUs and with ≥ 1 BSI during the 20-month study period. BSIs (all primary and health care-associated) were diagnosed in infants with symptoms suggestive of infection and classified prospectively as Of 557 BSIs identified in 494 patients, CoNS accounted for 378/557 (67.8%) and recognized bacterial or fungal pathogens for 179/557 (32.1%). Severe morbidity/mortality was reported in 148/557 (26.6%) BSIs. Independent factors associated with severe morbidity/mortality were corrected gestational age <28 weeks (CGA) at infection ( In BSIs in the NICU, severe morbidity/mortality was associated with low CGA at infection, FGR, and proven pathogen-related BSIs. When only one blood culture was positive, severe morbidity/mortality were less frequent if it grew with ClinicalTrials.gov (NCT02598609).

Sections du résumé

Background UNASSIGNED
Health care-associated primary bloodstream infections (BSIs), defined as not secondary to an infection at another body site, including central line-associated BSI, are a leading cause of morbidity and mortality in patients in neonatal intensive care units (NICUs). Our objective was to identify factors associated with severe morbidity and mortality after these infections in neonates in NICUs.
Methods UNASSIGNED
This ancillary study of the SEPREVEN trial included neonates hospitalized ≥2 days in one of 12 French NICUs and with ≥ 1 BSI during the 20-month study period. BSIs (all primary and health care-associated) were diagnosed in infants with symptoms suggestive of infection and classified prospectively as
Results UNASSIGNED
Of 557 BSIs identified in 494 patients, CoNS accounted for 378/557 (67.8%) and recognized bacterial or fungal pathogens for 179/557 (32.1%). Severe morbidity/mortality was reported in 148/557 (26.6%) BSIs. Independent factors associated with severe morbidity/mortality were corrected gestational age <28 weeks (CGA) at infection (
Conclusions UNASSIGNED
In BSIs in the NICU, severe morbidity/mortality was associated with low CGA at infection, FGR, and proven pathogen-related BSIs. When only one blood culture was positive, severe morbidity/mortality were less frequent if it grew with
Study registration UNASSIGNED
ClinicalTrials.gov (NCT02598609).

Identifiants

pubmed: 37325351
doi: 10.3389/fped.2023.1170863
pmc: PMC10264575
doi:

Banques de données

ClinicalTrials.gov
['NCT02598609']

Types de publication

Journal Article

Langues

eng

Pagination

1170863

Informations de copyright

© 2023 Jaloustre, Cohen, Biran, Decobert, Layese, Audureau, Le Saché, Chevallier, Boukhris, Bolot, Caeymaex, Tauzin and with SEPREVEN study Group.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Pediatrics. 2006 Oct;118(4):1332-40
pubmed: 17015521
Antibiotics (Basel). 2022 Jun 02;11(6):
pubmed: 35740171
Lancet Respir Med. 2018 Mar;6(3):223-230
pubmed: 29508706
Pediatrics. 2002 Aug;110(2 Pt 1):285-91
pubmed: 12165580
Neonatology. 2011;99(1):23-31
pubmed: 20588067
Cochrane Database Syst Rev. 2016 Apr 20;4:CD008436
pubmed: 27095103
J Infect Chemother. 2016 Dec;22(12):785-789
pubmed: 27645121
Pediatrics. 2005 Sep;116(3):595-602
pubmed: 16140698
JAMA. 2004 Nov 17;292(19):2357-65
pubmed: 15547163
JAMA. 2015 Sep 8;314(10):1039-51
pubmed: 26348753
Pediatr Infect Dis J. 2007 Jul;26(7):607-12
pubmed: 17596803
BMC Pediatr. 2010 Nov 19;10:84
pubmed: 21092087
Arch Dis Child Fetal Neonatal Ed. 2011 Jan;96(1):F9-F14
pubmed: 20876594
Eur J Clin Microbiol Infect Dis. 2020 Nov;39(11):2185-2194
pubmed: 32519215
World J Pediatr. 2018 Jun;14(3):269-273
pubmed: 29536341
J Pediatr. 2015 May;166(5):1193-9
pubmed: 25919728
Pediatr Infect Dis J. 1998 Jul;17(7):593-8
pubmed: 9686724
Pediatr Infect Dis J. 2014 Jan;33(1):e7-e13
pubmed: 23899966
Pediatr Infect Dis J. 2014 Mar;33(3):238-43
pubmed: 24030351
Pediatr Infect Dis J. 2002 Jan;21(1):22-7
pubmed: 11791093
Curr Opin Infect Dis. 2010 Jun;23(3):208-16
pubmed: 20179594
PLoS One. 2019 Nov 22;14(11):e0225407
pubmed: 31756213
J Perinatol. 2002 Oct-Nov;22(7):547-9
pubmed: 12368970
Microbiol Spectr. 2018 Aug;6(4):
pubmed: 30117414
J Hosp Infect. 2003 Jan;53(1):25-30
pubmed: 12495682
Virulence. 2018 Jan 1;9(1):621-633
pubmed: 29405832
Pediatr Infect Dis J. 2017 Aug;36(8):774-779
pubmed: 28709162
J Hosp Infect. 2016 Sep;94(1):95-8
pubmed: 27424947
J Matern Fetal Neonatal Med. 2021 Mar;34(5):780-786
pubmed: 31072183
Lancet Infect Dis. 2017 Apr;17(4):381-389
pubmed: 28089444
Clin Dev Immunol. 2013;2013:586076
pubmed: 23762094
Am J Infect Control. 2012 Feb;40(1):59-64
pubmed: 21839544
Clin Infect Dis. 2009 Jul 1;49(1):1-45
pubmed: 19489710
Am J Infect Control. 2007 Apr;35(3):177-82
pubmed: 17433941
Clin Microbiol Infect. 2014 Nov;20(11):O928-35
pubmed: 24796697
Am J Perinatol. 2015 Jun;32(7):675-82
pubmed: 25486288
Lancet. 2017 Oct 14;390(10104):1770-1780
pubmed: 28434651
J Pediatr. 2013 Jun;162(6):1120-4, 1124.e1
pubmed: 23324523
J Perinatol. 2004 Mar;24(3):175-80
pubmed: 14985775
Curr Opin Pediatr. 2016 Apr;28(2):141-9
pubmed: 26886785
Lancet. 2022 Jan 22;399(10322):384-392
pubmed: 35065786

Auteurs

Morgane Jaloustre (M)

Neonatal Intensive Care Unit, Centre Hospitalier Intercommunal de Creteil, Creteil, France.

Robert Cohen (R)

Neonatal Intensive Care Unit, Centre Hospitalier Intercommunal de Creteil, Creteil, France.
Faculty of Medicine, University Paris Est Creteil, Creteil, France.
Groupe de Pathologie Infectieuse Pédiatrique, Paris, France.

Valérie Biran (V)

Neonatal Intensive Care Unit, APHP, CHU Robert Debré, Paris, France.

Fabrice Decobert (F)

Neonatal Intensive Care Unit, Centre Hospitalier Intercommunal de Creteil, Creteil, France.

Richard Layese (R)

Assistance Publique-Hôpitaux de Paris AP-HP, Hôpital Henri Mondor, Unité de Recherche Clinique (URC Mondor), Creteil, France.
University Paris Est Creteil, INSERM, IMRB, CEpiA Team, Creteil, France.

Etienne Audureau (E)

Assistance Publique-Hôpitaux de Paris AP-HP, Hôpital Henri Mondor, Unité de Recherche Clinique (URC Mondor), Creteil, France.
University Paris Est Creteil, INSERM, IMRB, CEpiA Team, Creteil, France.

Nolwenn Le Saché (N)

Pediatric Intensive Care and Neonatal Medicine, Bicêtre Hospital, AP-HP, Le Kremlin-Bicêtre, France.

Marie Chevallier (M)

Neonatal Intensive Care Unit, CHU Grenoble Alpes, Grenoble, France.

Mohamed Riadh Boukhris (MR)

Department of Neonatology, CHU Lille, Lille, France.

Pascal Bolot (P)

Neonatal Intensive Care Unit, Centre Hospitalier de Saint-Denis, Saint-Denis, France.

Laurence Caeymaex (L)

Neonatal Intensive Care Unit, Centre Hospitalier Intercommunal de Creteil, Creteil, France.
Faculty of Medicine, University Paris Est Creteil, Creteil, France.

Manon Tauzin (M)

Neonatal Intensive Care Unit, Centre Hospitalier Intercommunal de Creteil, Creteil, France.

Classifications MeSH